Alembic Pharmaceuticals intimates of grant of Fast Track Designation for cancer drug

By USFDA to Rhizen Pharmaceuticals SA (an associate company)

Alembic Pharmaceuticals announced that its associate company, Rhizen Pharmaceuticals SA has been granted by USFDA Fast Track Designation for RP6530 (tenalisib), a highly dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed / refractory peripheral T-cell lymphoma.

Powered by Capital Market - Live News